Harbin Gloria Pharmaceuticals Co., Ltd

002437.SZ

002437.SZHarbin Gloria Pharmaceuticals Co., Ltd CN flag

Shenzhen Stock Exchange

2.80

CNY

+0.03

(+1.08%)

0.11EPS

25.45P/E

6.08BMarket Cap

Apr 24Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

CNE100000QG8

Return %

Stock

S&P500

66.67

9.50

12.45

58.73

-11.11

91.32

Use logarithmic scale

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	0.34	0.62	0.91	1.25	1.37	1.38	2.49	2.3	1.39	1.43	1.41	1.19	1.11	1.09
Basic EPS, GAAP	0.08	0.11	0.21	0.31	0.33	0.14	0.06	-1.21	0.18	0.02	-0.13	0.05	0.11	0.11
Free Cash Flow per Basic Share	0.03	0.14	0.26	0.2	0.39	0.21	0.48	0.26	-0.01	0.11	0.1	0.11	0.16	-0.03
Dividend per Share	- -	0.08	0.03	0.07	0.12	0.12	0.08	0.08	0.06	0.03	0.03	0.02	- -	- -
Book Value per Share	0.36	0.38	0.79	1.02	1.55	1.61	1.64	0.42	0.6	0.51	0.53	0.58	0.73	0.74
Tangible Book Value per Share	1.06	0.79	0.4	-0.3	-0.05	-0.04	0.21	0.34	0.53	0.58	0.5	0.52	0.65	0.63
Basic Weighted Avg Shares	2,095	2,126	2,100	2,145	2,179	2,198	2,197	2,198	2,198	2,197	2,199	2,200	2,198	2,199
Sales/Revenue/Turnover	711	1,308	1,906	2,681	2,984	3,042	5,481	5,054	3,055	3,145	3,108	2,626	2,441	2,399
Operating Margin (%)	22.3	13.83	26.64	32.09	31.18	18.31	11.58	8.79	-0.57	5.58	4.38	9.37	11.99	11.46
Depreciation Expense	26	62	92	144	155	176	184	181	149	144	130	104	92	- -
Net Income, GAAP	165	227	444	665	717	310	126	-2,662	400	45	-291	120	233	241
Effective Tax Rate (%)	17.92	14.8	16.79	15.11	15.13	17.76	28.04	- -	27.68	37.38	- -	27.2	14.51	12.5
Profit Margin (%)	23.17	17.34	23.28	24.79	24.02	10.18	2.3	-52.67	13.1	1.43	-9.37	4.58	9.54	10.04
Working Capital	1,720	1,036	95	-1,939	-1,508	-1,244	-1,202	-1,563	-761	-478	-520	-257	54	55
LT Debt	15	- -	337	300	973	1,455	997	1	11	- -	- -	- -	2	2
Total Equity	2,361	2,478	3,102	3,473	4,047	4,253	4,448	1,588	1,933	1,979	1,704	1,710	1,973	1,958
Return on Invested Capital (%)	5.61	6.26	12.12	12.56	10.5	5.8	5.84	- -	-0.33	3.2	- -	6.37	11.29	10.98
Return on Capital (%)	18.55	24.53	23.28	15.79	12.2	6.28	3.37	- -	14.13	2.93	- -	6.09	12.74	13.12
Return on Common Equity (%)	24.15	29.11	36.21	34.57	25.68	8.95	3.52	-117.35	35.58	3.7	-25.59	9.83	16.14	15.86

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	6.6%	-12.07%	-7.06%
Net Income, GAAP	-327.13%	-199.69%	93.43%
Free Cash Flow	-81.78%	-187.29%	42.32%
Total Cash Common Dividend	0.42%	-37.43%	-78.64%
Total Equity	-0.02%	5.18%	15.36%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Mr. Leifeng Guo
Full Time Employees: 3,085
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Address: No. 29, Beijing Road Harbin People's Republic of China 150025
IPO Date: Oct 27, 2011
Website: gloria.cc
Similar Companies: Aarti Drugs Limited (AARTIDRUGS.NS)
Digital Utilities Ventures, Inc. (DUTV)
Green Hygienics Holdings Inc. (GRYN)
Vinergy Capital Inc. (VIN.CN)
CanaFarma Hemp Products Corp. (CNFHF)
Canzon Israel Ltd (CNZN.TA)
Business: Harbin Gloria Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products primarily in the People's Republic of China. It offers cardiac cerebrovascular medication, skeletal muscle system, vitamins and minerals, urinary system medication, antitumor medication, endocrine medicine, anti-infective drugs, respiratory medication, antihistamine, peptic, and other products. Harbin Gloria Pharmaceuticals Co., Ltd. was founded in 2000 and is based in Harbin, the People's Republic of China.

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	0.34	0.62	0.91	1.25	1.37	1.38	2.49	2.3	1.39	1.43	1.41	1.19	1.11	1.09
Basic EPS, GAAP	0.08	0.11	0.21	0.31	0.33	0.14	0.06	-1.21	0.18	0.02	-0.13	0.05	0.11	0.11
Free Cash Flow per Basic Share	0.03	0.14	0.26	0.2	0.39	0.21	0.48	0.26	-0.01	0.11	0.1	0.11	0.16	-0.03
Dividend per Share	- -	0.08	0.03	0.07	0.12	0.12	0.08	0.08	0.06	0.03	0.03	0.02	- -	- -
Book Value per Share	0.36	0.38	0.79	1.02	1.55	1.61	1.64	0.42	0.6	0.51	0.53	0.58	0.73	0.74
Tangible Book Value per Share	1.06	0.79	0.4	-0.3	-0.05	-0.04	0.21	0.34	0.53	0.58	0.5	0.52	0.65	0.63
Basic Weighted Avg Shares	2,095	2,126	2,100	2,145	2,179	2,198	2,197	2,198	2,198	2,197	2,199	2,200	2,198	2,199
Sales/Revenue/Turnover	711	1,308	1,906	2,681	2,984	3,042	5,481	5,054	3,055	3,145	3,108	2,626	2,441	2,399
Operating Margin (%)	22.3	13.83	26.64	32.09	31.18	18.31	11.58	8.79	-0.57	5.58	4.38	9.37	11.99	11.46
Depreciation Expense	26	62	92	144	155	176	184	181	149	144	130	104	92	- -
Net Income, GAAP	165	227	444	665	717	310	126	-2,662	400	45	-291	120	233	241
Effective Tax Rate (%)	17.92	14.8	16.79	15.11	15.13	17.76	28.04	- -	27.68	37.38	- -	27.2	14.51	12.5
Profit Margin (%)	23.17	17.34	23.28	24.79	24.02	10.18	2.3	-52.67	13.1	1.43	-9.37	4.58	9.54	10.04
Working Capital	1,720	1,036	95	-1,939	-1,508	-1,244	-1,202	-1,563	-761	-478	-520	-257	54	55
LT Debt	15	- -	337	300	973	1,455	997	1	11	- -	- -	- -	2	2
Total Equity	2,361	2,478	3,102	3,473	4,047	4,253	4,448	1,588	1,933	1,979	1,704	1,710	1,973	1,958
Return on Invested Capital (%)	5.61	6.26	12.12	12.56	10.5	5.8	5.84	- -	-0.33	3.2	- -	6.37	11.29	10.98
Return on Capital (%)	18.55	24.53	23.28	15.79	12.2	6.28	3.37	- -	14.13	2.93	- -	6.09	12.74	13.12
Return on Common Equity (%)	24.15	29.11	36.21	34.57	25.68	8.95	3.52	-117.35	35.58	3.7	-25.59	9.83	16.14	15.86

	Sep'24	Dec'24	Mar'25
ST Debt	36	1	71
LT Borrowings	9	- -	- -
LT Finance Leases	4	2	2
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	2,281	2,280	2,247
Market Capitalization	5,028	5,540	5,344

	Sep'24	Dec'24	Mar'25
Total Current Assets	870	877	947
Accounts Receivable, Net	161	125	107
Cash, Cash Equivalents & STI	469	512	602
Inventories	188	189	186
Total Current Liabilities	872	823	892
Payables & Accruals	- -	- -	- -
ST Debt	36	1	71
Deferred Revenue	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2023	681	751	619	574	2,626
2024	593	628	636	583	2,441
2025	551	- -	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2023	0.01	- -	- -	- -	0.05
2024	0.02	- -	- -	- -	0.11
2025	0.03	- -	- -	- -	- -

Harbin Gloria Pharmaceuticals Co., Ltd

Growth Rates

(avg. rate of change)

Company Description

Growth Rates

(avg. rate of change)

Capital Structure

Working Capital

Quarterly Dividends Per Share

Year

Quarterly Revenue

Year

Quarterly Earnings Per Share

Year